The greatest barrier here is the FDA. They don't let you perform medical interventions (even breakthroughs like this) without going through a rigorous process. Companies like Editas ($43M Series A) are going through those motions right now.
Long-term, where I live will depend on the above outcome.
Note that the FDA does allow some compassionate use of experimental medications and technologies in extreme cases. I'm not familiar with Editas's regulatory strategy but it wouldn't be crazy for them to pursue that avenue for, say, a child cancer patient as an early step. But even they will be cautious, as any misstep (i.e., harm to a patient) will have major negative consequences for the technology as a whole.